Progress of ADAM17 in Fibrosis-Related Diseases
Fibrosis leads to structural damage and functional decline and is characterized by an accumulation of fibrous connective tissue and a reduction in parenchymal cells. Because of its extremely poor prognosis, organ fibrosis poses a significant economic burden. In order to prevent and treat fibrosis mo...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/mi/9999723 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850211506261590016 |
|---|---|
| author | Suyan Yan Yaqi Zhao Yuyu Yang Baocheng Liu Wei Xu Zhenzhen Ma Qingrui Yang |
| author_facet | Suyan Yan Yaqi Zhao Yuyu Yang Baocheng Liu Wei Xu Zhenzhen Ma Qingrui Yang |
| author_sort | Suyan Yan |
| collection | DOAJ |
| description | Fibrosis leads to structural damage and functional decline and is characterized by an accumulation of fibrous connective tissue and a reduction in parenchymal cells. Because of its extremely poor prognosis, organ fibrosis poses a significant economic burden. In order to prevent and treat fibrosis more effectively, potential mechanisms need to be investigated. A disintegrin and metalloprotease 17 (ADAM17) is a membrane-bound protein. It regulates intracellular signaling and membrane protein degradation. Fibrosis mediated by ADAM17 has been identified as an important contributor, although the specific relationship between its multiple regulatory functions and the pathogenesis is unclear. This article describes ADAM17 activation, function, and regulation, as well as the role of ADAM17 mediated fibrosis injury in kidney, liver, heart, lung, skin, endometrium, and retina. To develop new therapeutic approaches based on ADAM17 related signal pathways. |
| format | Article |
| id | doaj-art-18945e85ed544a8a9f6a2e12e5cf1a58 |
| institution | OA Journals |
| issn | 1466-1861 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-18945e85ed544a8a9f6a2e12e5cf1a582025-08-20T02:09:32ZengWileyMediators of Inflammation1466-18612025-01-01202510.1155/mi/9999723Progress of ADAM17 in Fibrosis-Related DiseasesSuyan Yan0Yaqi Zhao1Yuyu Yang2Baocheng Liu3Wei Xu4Zhenzhen Ma5Qingrui Yang6Department of Rheumatology and ImmunologyDepartment of Rheumatology and ImmunologyUCL School of PharmacyDepartment of Rheumatology and ImmunologyDepartment of Rheumatology and ImmunologyDepartment of Rheumatology and ImmunologyDepartment of Rheumatology and ImmunologyFibrosis leads to structural damage and functional decline and is characterized by an accumulation of fibrous connective tissue and a reduction in parenchymal cells. Because of its extremely poor prognosis, organ fibrosis poses a significant economic burden. In order to prevent and treat fibrosis more effectively, potential mechanisms need to be investigated. A disintegrin and metalloprotease 17 (ADAM17) is a membrane-bound protein. It regulates intracellular signaling and membrane protein degradation. Fibrosis mediated by ADAM17 has been identified as an important contributor, although the specific relationship between its multiple regulatory functions and the pathogenesis is unclear. This article describes ADAM17 activation, function, and regulation, as well as the role of ADAM17 mediated fibrosis injury in kidney, liver, heart, lung, skin, endometrium, and retina. To develop new therapeutic approaches based on ADAM17 related signal pathways.http://dx.doi.org/10.1155/mi/9999723 |
| spellingShingle | Suyan Yan Yaqi Zhao Yuyu Yang Baocheng Liu Wei Xu Zhenzhen Ma Qingrui Yang Progress of ADAM17 in Fibrosis-Related Diseases Mediators of Inflammation |
| title | Progress of ADAM17 in Fibrosis-Related Diseases |
| title_full | Progress of ADAM17 in Fibrosis-Related Diseases |
| title_fullStr | Progress of ADAM17 in Fibrosis-Related Diseases |
| title_full_unstemmed | Progress of ADAM17 in Fibrosis-Related Diseases |
| title_short | Progress of ADAM17 in Fibrosis-Related Diseases |
| title_sort | progress of adam17 in fibrosis related diseases |
| url | http://dx.doi.org/10.1155/mi/9999723 |
| work_keys_str_mv | AT suyanyan progressofadam17infibrosisrelateddiseases AT yaqizhao progressofadam17infibrosisrelateddiseases AT yuyuyang progressofadam17infibrosisrelateddiseases AT baochengliu progressofadam17infibrosisrelateddiseases AT weixu progressofadam17infibrosisrelateddiseases AT zhenzhenma progressofadam17infibrosisrelateddiseases AT qingruiyang progressofadam17infibrosisrelateddiseases |